Board of Directors
Pini Orbach, PhD Chairman
Dr. Orbach is the Head of the Pharma Division of Arkin Holdings. Dr. Orbach is a member of the board in several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics - a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. He holds a PhD from the University of Florida, and was a postdoctoral fellow at Harvard Medical School - Massachusetts General Hospital.
Ruth Ben Yakar, PhD CEO
Dr. Ben Yakar has over 20 years of experience in the biomedical field, including 17 years of management in the biotech industry, leading diverse corporate, financial, business, operational, clinical, and regulatory activities. Dr. Ben Yakar also serves as a Director at biotech companies traded on Nasdaq. Prior to joining BioSight, Dr. Ben Yakar served in several executive management positions, including CEO of Procognia, a public biotech company, CEO of Thrombotech, a Phase 2b biotech company she led towards acquisition, Director at Israel Advanced Technology Industries organization, Chief Business Officer of YEDA, the technology transfer company of the Weizmann Institute of Science, and Vice President at Gamida Cell, a Phase 3 biotech company. Dr. Ben Yakar holds a PhD Cum Laude in molecular cell biology from the Weizmann Institute of Science.
Briggs Morrison, MD
Dr. Briggs Morrison brings BioSight over 22 years of experience in business and clinical management positions in the pharmaceutical industry. Dr Morrison currently serves as an Executive Partner at MPM Capital and CEO at Syndax, and was formerly Executive Vice President Global Medicines Development and Chief Medical Officer at AstraZeneca, Vice President Clinical Sciences, Oncology at Merck & Co. and Head of Medical Affairs, Safety and Regulatory Affairs for Pfizer.
Mr. Sasson is a member of the Board of Directors of CancerLinQ™ LLC, a subsidiary of the American Society of Clinical Oncology (ASCO) established for the development and operations of the CancerLinQ™ initiative, as well as The Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO), which seeks dramatic advances in the prevention, diagnosis, treatment, and cure of all types of cancer.
Mr. Sasson is also the founder of several technology comapnies, lead by Mr. Sasson to technological and commercial success.
Liora Ettinger, MBA
Mrs. Ettinger is the CEO of Michael Ilan Management and Investment Ltd. Mrs. Ettinger obtained a B.A. in Economics and Business Administration (Highest Honors) from Bar-Ilan University, and an MBA with a specialization in Finance and Accounting from Tel Aviv University. She has been involved in financial management in leading Israeli companies and foreign markets, specializing in corporate finance, deal structuring, public offerings, M&A, and business analysis.
Yeshai Kav, MBA
Yeshai Is Certified Investment Advisor licensed with the Israeli Securities Authority, Yeshai serves as the Chief Investment officer at MSA Shine Global family office Ltd., Prior to joining MSA, Yeshai held senior investment advisory positions at two leading Israeli banks. Yeshai specializes in financing, risk management and strategy.
Stela Gengrinovitch, PhD Founder, Chief Scientist
Dr. Stela Gengrinovitch founded BioSight on year 2000. Dr. Gengrinovitch has accumulative experience of over 20 years in cell biology, enzymology and biochemistry. Prior to founding BioSight, Dr. Gengrinovitch served as a fellow academic researcher and published several articles in well known scientific journals. Dr. Gengrinovitch also served as a Research and Development Manager at Enzymotec. Dr. Gengrinovitch holds a BSc degree in chemistry and a PhD degree in biochemistry from the Technion Institute of Technology.